Clinical Trial Update: Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of abemaciclib with pembrolizumab in metastatic or recurrent head and neck cancer was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Head and Neck Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-07-09